Light activated immunomodulation and in situ scaffolding to enhance MSC therapy

The National Institute of General Medical Sciences awarded the University of Maryland Eastern Shore $143,000 on July 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to design, synthesize, and characterize a light-activated hydrogel platform that integrates local immunomodulation with in situ scaffolding to enhance human mesenchymal stem cell therapy.

The project addresses two clinical barriers limiting HMSC-based therapies: immune-mediated clearance of transplanted cells and poor retention and engraftment within injured tissues. The proposed light-activated hydrogel platform uses a photocaged complex to enable precise, on-demand release of immunomodulators while providing mechanical support, creating what the project describes as a "regenerative niche" that is both immune-compatible and structurally supportive. The work spans two aims: design and characterization of the BEPA-photocaged hydrogel complex for controlled immunomodulator and hydrogel formation, and preclinical evaluation of the complex for immune-permissive and extracellular-matrix-mimetic stem cell engraftment.

Performance occurs in Maryland, with an ultimate completion date of May 31, 2030. The award carries an assistance type of Project Grant, reflecting competitive research funding rather than formula allocation or cooperative agreement structure.

Abstract

Human mesenchymal stem cells (hmscs) can be isolated from various adult tissues including bone marrow, FAT tissues, dental pulp and synovium, and exhibit therapeutic promise for tissue repair, regeneration, and treatment of chronic immune and degenerative diseases due to their multipotent differentiation ability, trophic factor secretion, and immunomodulatory functions. However, their clinical efficacy remains limited by two barriers: (i) immune-mediated clearance of transplanted cells and (II) poor retention and engraftment within injured tissues. Even autologous or well-matched allogeneic hmscs are frequently recognized as "non-self" after their transplantation, leading to rapid cell loss before therapeutic benefits are realized. Overcoming immune rejection and microenvironmental insufficiency is therefore critical to advance hmsc-based therapies. Systemic immunomodulators can partially mitigate host rejection but often cause off-target effects, while conventional scaffolding like hydrogels provides structural support yet rarely influences immune responses. To address these limitations, we propose a light-activated hydrogel platform that integrates local immunomodulation with in situ scaffolding under a single, spatiotemporally defined stimulus. To achieve this objective, we will pursue two aims: 1) design, synthesis and characterization of bepa-photocaged hydrogel complex for controlled immunomodulator and hydrogel formation, and 2) preclinical evaluation of bepa- photocaged hydrogel complex for immune-permissive and ECM-mimetic stem cell engraftment. The proposed platform is expected to establish a "regenerative niche" that is both immune-compatible and mechanically supportive, thereby improving hmsc survival, retention, and integration. The approach is innovative in three ways: (i) a light-activated photocage enabling precise, on-demand immunomodulation, (II) an injectable, light- triggering hydrogelator that surpasses conventional scaffolds, and (III) a unified near-infrared (NIR) control axis that simultaneously regulates immune modulation and scaffold formation. By converting engraftment into a programmable event, this strategy provides effectively spatiotemporal control over stem cell transplantation. The anticipated outcome is a safer and more effective platform for regenerative medicine with broad translational potential.